Chiesi Farmaceutici Announces New Mexico Affiliate
PARMA, Italy, October 25, 2012 /PRNewswire/ –
The Italian Group, which generates 72% of its turnover outside Italy,
continues with its internationalisation strategy in Latin America
Chiesi Farmaceutici S.p.A., a multinational pharma group based in Parma, Italy, has
recently opened its 25th affiliate, Chiesi Mexico, representing a milestone in the
company’s internationalisation plan, which began in 1978.
Directed by Manuel Cosme Odabachian, the Mexican affiliate will firstly focus on the
Special Care sector with its natural surfactant for neonate respiratory distress syndrome,
and then extend commercial activities to drugs for respiratory diseases.
“Mexico,” underlines Alberto Chiesi, Chiesi Group President, “is the second most
important pharmaceutical market in Latin America, and has grown considerably in recent
years. This, combined with national healthcare policies designed to provide for almost the
entire population, has prompted us to invest in this country. As a company firmly rooted
in Italy, we regret the fact that our country cannot boast the same prospects. Yet recent
governmental decisions regarding prices encourage pharma investors to look elsewhere.”
According to CEO Ugo Di Francesco, “Mexico is a key element in the development
strategy adopted by the Group for the next few years. Our therapeutic range, based on a
combination of specialist drugs and widely-distributed products, aims to respond to the
needs of a large country which is continually improving healthcare for its citizens.”
Last year Chiesi Group consolidated sales, 72% of which was generated outside the
domestic market, reached 1,057 million Euro (+4.1% on 2010). R&D investments in 2011
totalled 170 million Euro, around 16% of sales, placing Chiesi top among Italian pharma
companies and 13th among European pharmaceutical companies for R&D investment (EU
Industrial R&D Investment Scoreboard).
Further growth is planned for 2012 to exceed sales of 1,100 million Euro and ensure
R&D investment levels are maintained at over 180 million Euro.
“The Chiesi Group’s particular focus,” highlights Paolo Chiesi, Vice President and R&D
Director, “has always been Research and Development and this will continue to be crucial
to our growth plan. We are satisfied with the results for 2011, especially at a time when
all markets are experiencing significant difficulty, including Europe, which is close to
stagnation. Despite this difficulty, we intend to continue investing in innovation, as we
believe this is the only way to sustain growth.”
SOURCE Chiesi Farmaceutici S.p.A.